5/11/2025

During the quarter, apparent uncertainty about US industrial, tax and trade policy appeared to dampen equity market performance, particularly in the US. Read more here.

Source: SeekingAlpha

5/9/2025

The consensus price target hints at a 27.9% upside potential for Astrazeneca (AZN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Source: Yahoo

5/9/2025

NVO and JAZZ report first-quarter results. AZN's asthma study on Breztri meets key goals.

Source: Yahoo

5/9/2025

WILMINGTON, Del., May 09, 2025--Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca’s IMFINZI® (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) compared to BCG induction and maintenance therapy alone.​

Source: Yahoo

5/9/2025

It has been ten months since I last updated the UK top 40 dividend stocks list, and much has happened since then.Trump has been doing his best to shake up...

Source: SeekingAlpha

5/9/2025

Invesco International Diversified Fund offers investors broad-based exposure to non-US equities by combining 4 portfolios that varied individual mandates regarding region & company size.

Source: SeekingAlpha

5/9/2025

Our actively managed, bottom-up stock selection drives the fund’s sector, country and regional allocations.

Source: SeekingAlpha

5/8/2025

The Hartford International Growth Fund (I Share) underperformed the MSCI ACWI ex USA Growth Net Index during the quarter. Read more here.

Source: SeekingAlpha

5/8/2025

The trial’s primary endpoint is pCR, with secondary endpoints including event-free survival (EFS), overall survival, safety, and invasive disease-free survival.

Source: Yahoo

5/8/2025

BeiGene's innovative cancer treatments, Brukinsa and Tevimbra, are driving growth. Click for a look at ONC and its latest earnings results.

Source: SeekingAlpha

5/7/2025

Hartford International Equity Fund (I Share) (6.01%) outperformed the MSCI ACWI ex USA Index (Net) (5.23%) during the quarter. Read more here.

Source: SeekingAlpha

5/7/2025

AstraZeneca (LSE:AZN) recently experienced positive developments, including the European approval of Calquence for mantle cell lymphoma and promising Phase III trial results for ENHERTU in breast cancer. These advances in oncology could add depth to the company's market performance. Meanwhile, broader market trends showed mixed movements, with the Dow Jones and S&P 500 rising, while Nasdaq slipped slightly. Despite a flat market overall last week due to investor anticipation of the Federal...

Source: Yahoo

5/7/2025

The Hartford International Opportunities Fund (I Share) outperformed the MSCI ACWI ex-USA Index during the quarter. Read more here.

Source: SeekingAlpha

5/7/2025

Q1 2025 Arcus Biosciences Inc Earnings Call

Source: Yahoo

5/7/2025

A panel at Swiss Biotech Day 2025 discussed three global parallel drug approval pathways.

Source: Yahoo

5/7/2025

WILMINGTON, Del., May 07, 2025--Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients with h

Source: Yahoo

5/7/2025

The EC’s decision was supported by outcomes from the ECHO Phase III trial.

Source: Yahoo

5/7/2025

Tempus AI Inc (TEM) reports a 75.4% revenue increase and a significant $200 million partnership, setting the stage for a promising fiscal year.

Source: Yahoo

5/6/2025

Source: SeekingAlpha

5/6/2025

AstraZeneca has opened its first U.S.-operated cell therapy manufacturing plant in Rockville, Maryland, as part of its ongoing $3.5 billion investment in American innovation.

Source: Yahoo